People: iCo Therapeutics Inc (ICO.V)

ICO.V on TSX Venture Exchange

0.05CAD
2:05pm EDT
Price Change (% chg)

$0.00 (+0.00%)
Prev Close
$0.05
Open
$0.05
Day's High
$0.05
Day's Low
$0.04
Volume
112,500
Avg. Vol
564,835
52-wk High
$0.59
52-wk Low
$0.04

Search Stocks

Summary

Name Age Since Current Position

William Jarosz

2008 Independent Chairman of the Board

Andrew Rae

2005 President, Chief Executive Officer, Director

W. John Meekison

2008 Chief Financial Officer, Corporate Secretary

Peter Hnik

51 2010 Chief Medical Officer

Richard Barker

65 2006 Independent Director

Noel Hall

45 2008 Independent Director

Douglas Janzen

41 2012 Independent Director

Michael Moore

IR Contact Officer

Biographies

Name Description

William Jarosz

Mr. William Jarosz, J.D., is Independent Chairman of the Board of iCo Therapeutics Inc. William Jarosz is currently a Partner at Cartesian Capital Group, LLC, a global investment management firm. From 1997 until 2005, Mr. Jarosz served as Managing Director and General Counsel of AIG Capital Partners, a subsidiary of American International Group, Inc., and as Managing Director of the AIG-Brunswick Millennium Fund. While at AIG Capital Partners, Mr. Jarosz oversaw global private equity transactions for the firm's various private equity funds. Prior to joining AIG in 1997, Mr. Jarosz practiced law at Debevoise & Plimpton, specializing in international private equity investment and Russian corporate and securities laws. Mr. Jarosz also served as a consultant to the World Bank on the regulation of Foreign Direct Investment in emerging markets. Mr. Jarosz is a graduate of the University of Montana, and received an MA in Law and Diplomacy from the Fletcher School at Tufts University and a JD from Harvard Law School.

Andrew Rae

Mr. Andrew J. Rae is President, Chief Executive Officer and Director of iCo Therapeutics Inc. Andrew Rae is the Chief Executive Officer and President of the Company on a full-time basis. Mr. Rae has spent a decade in the biotechnology industry, formerly as CFO with Ability Biomedical Corporation (Irvine CA, Vancouver BC), acquired by Medarex, Inc. in 2004. Mr. Rae has also served as Vice President, Finance & Corporate Affairs at Active Pass Pharmaceuticals (Vancouver BC). In his various roles, Mr. Rae has raised approximately $50M in venture, strategic and capital markets financings, engaged in a successful cross-border M&A transaction, and played a significant role in shaping multiple business development deals (Cambridge Antibody, Isis Pharmaceuticals, Medarex). Prior to his operational experiences, Mr. Rae served as Biotechnology Equities Analyst, Goepel Shields & Partners (now Raymond James Canada), covering Canadian biotechnology stocks including Angiotech Pharmaceuticals, QLT Inc. and ID Biomedical. Mr. Rae currently sits on the Dean's External Advisory Board for the Faculty of Business Administration at Simon Fraser University, the BCIT/University of British Columbia BSc in Biotechnology, Honours Program Advisory Committee, and the Board of Directors of Covenant House Vancouver, a charity operating shelters and counsel to homeless youth in Vancouver, BC. In 2009 Andrew was Pacific Finalist, Ernst & Young Entrepreneur of the Year (Canada). Mr. Rae's degrees include a B.Sc. from the University of Western Ontario and an MBA from Simon Fraser University.

W. John Meekison

Mr. W. John Meekison is Chief Financial Officer and Corporate Secretary of iCo Therapeutics Inc. Mr. Meekison has over 15 years experience as an investment banker specializing in life sciences at Loewen, Ondaatje, McCutcheon Limited, Haywood Securities Inc., Dlouhy Merchant Group Inc. and Pacific International Securities Inc. As a financier, Mr. Meekison has raised equity capital for various biotechnology companies such as StressGen Biotechnologies Corporation (now Nventa Biopharmaceuticals Corporation), ID Biomedical Corp., Salix Pharmaceuticals Inc., Acorda Therapeutics Inc., Inex Pharmaceuticals Corporation, Nortran Pharmaceuticals Corp. (now Cardiome Pharma Corp.) and BioMS Medical Corp. Mr. Meekison has also acted as chief financial officer for Response Biomedical Corp., a TSX-listed company developing a novel clinical diagnostic platform, and as a director for Contec Innovations Inc., a TSX Venture-listed company. Mr. Meekison received his Bachelor of Arts from the University of British Columbia and is a Certified Investment Manager and Professional Logistician.

Peter Hnik

Dr. Peter Hnik, M.D. is the Chief Medical Officer of iCo Therapeutics Inc. Dr. Hnik received his medical degree from the Medical Faculty of Charles University of Prague in 1981. After practicing for several years at university’s eye clinic, where he performed surgery and provided consultation services regarding glaucoma and neuro-ophthalmology, Dr. Hnik joined the eye clinic at the University of British Columbia, as part of the glaucoma research group. He received his Master of Health Sciences degree from the University of British Columbia in 1999. Prior to joining the Company, Dr. Hnik served as associate director of clinical research with QLT Inc., where he played a critical role in designing and directing clinical trials for treatment of age-related macular degeneration and diabetic retinopathy with Visudyne. He was also heavily involved in the publication, in-licensing and pharmacovigilance activities for Visudyne. Dr. Hnik is a member of the Association for Research in Vision and Ophthalmology, the American Academy of Ophthalmology, the New York Academy of Sciences, the European Society of Retina Specialists and the Drug Information Association.

Richard Barker

Dr. Richard W. Barker is an Independent Director of iCo Therapeutics Inc. Richard is a strategic advisor, speaker and author on healthcare and life sciences. He is Director of the Centre for the Advancement of Sustainable Medical Innovation, a major European initiative aimed at transforming the R&D and regulatory processes in life sciences to bring advances more rapidly and affordably to patients. His 25-year business career in healthcare has spanned biopharmaceuticals, diagnostics and medical informatics – both in the USA and Europe. Most recently he was Director General of the Association of the British Pharmaceutical Industry, member of the Executive Committee of EFPIA (the European industry association) and Council member of IFPMA (the international equivalent). As a co-founder of Life Sciences UK, member of the NHS Stakeholder Forum, vice-chair of the UK Clinical Trials Collaboration and in many other roles, he has advised successive UK governments on healthcare issues, especially those relating to developing, valuing and using new healthcare technologies. He is also chairman of the South London Academic Health Science Network, accelerating innovation in this region of the NHS, and Chairman of Stem Cells for Safer Medicines, a public-private partnership developing stem cell technology for predicting the safety profile of new medicines. He is a board member of Celgene, a major US-based bio-therapeutics company and of iCo Therapeutics, a Canadian bioscience company.

Noel Hall

Mr. Noel Hall is an Independent Director of iCo Therapeutics Inc. Currently a consultant to the life sciences industry, Noel Hall has approximately 25 years experience in the biotechnology industry including most recently as co-founder and president of Aspreva Pharmaceuticals Corporation, which was acquired by the Galenica Group in January 2008 for aggregate consideration of US$915 million. Prior to co-founding Aspreva in December 2001, Mr. Hall held senior positions with consulting firm of Hill and Knowlton and served as head of global strategic planning for the firm’s worldwide pharmaceutical consulting practice. From 1992 to 1995, Mr. Hall was the director of corporate affairs for the United Kingdom and Northern Europe for The Wellcome Foundation Ltd., which is now part of GlaxoSmithKline PLC. From 1985 to 1990, Mr. Hall worked in market development with Abbott Laboratories Ltd. and from 1983 to 1985 Mr. Hall was a regional sales manager with Leo Laboratories Ltd. Mr. Hall holds an M.L.S.O. from Paddington Technical College, and is a director of privately held Vancouver based Zymeworks Inc.

Douglas Janzen

Mr. Douglas G. Janzen is Independent Director of iCo Therapeutics Inc. Mr Janzen has been involved in the Life Sciences industry for the past 19 years. He is currently the Founder of Northview Ventures, an entity which invests in and provides strategic advisory services to a number of technology companies. Previous to that he was President and CEO of Cardiome Pharma, a NASDAQ listed drug development company that completed an $800M licensing deal with Merck and saw its lead product Brinavess approved in Europe in 2010. Prior to that, Mr Janzen was an investment banker with Cormark Securities, acting as Managing Director of Life Sciences. Mr Janzen is the past Chairman of Life Sciences British Columbia, has served as a Director of Biotech Canada, and sits as a Director on a number of public and private boards. Mr Janzen is a past winner of Vancouver’s Top 40 under 40 award.

Michael Moore

Basic Compensation

Name Fiscal Year Total

William Jarosz

--

Andrew Rae

168,298

W. John Meekison

142,254

Peter Hnik

163,061

Richard Barker

--

Noel Hall

--

Douglas Janzen

--

Michael Moore

--
As Of 30 Dec 2012

Options Compensation

Name Options Value

William Jarosz

0 0

Andrew Rae

110,000 0

W. John Meekison

105,000 0

Peter Hnik

200,000 30,988

Richard Barker

0 0

Noel Hall

0 0

Douglas Janzen

0 0

Michael Moore

0 0
Search Stocks